Contact
Please use this form to send email to PR contact of this press release:
Data Safety Monitoring Board Confirms Triple Negative Breast Cancer as the Target Patient Population for Development of NeuVax™ (nelipepimut-S) in Combination with Trastuzumab (Herceptin®) in HER2 1+/2+ Breast Cancer Patients Following Final Analysis o…
TO: